NCT06082557

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

A Clinical Study on the Observation and Evaluation on the Safety and Efficacy of T60c Injection in the Treatment of Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open-labeled, single-arm, multiple-dose escalation and single-dose expansion clinical study of cell therapy to observe and evaluate the safety and efficacy of T60c injection in the treatment of patients with advanced solid tumors

Conditions

• Malignant Solid Tumors

Interventions

Type	Name	Description
DRUG	T60c injection	Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with "enhanced receptor" and "TROP2-CAR" (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion.

Timeline

• Start date: 2023-10-01
• Primary completion: 2025-03-01
• Completion: 2025-06-01
• First posted: 2023-10-13
• Last updated: 2023-10-13